ACURA PHARMACEUTICALS, INC
ACURA PHARMACEUTICALS, INC (ACUR): 3 pipeline candidates · ~1 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.1 months
D/E 3.83 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for ACURA PHARMACEUTICALS, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$20K
Cash
$65K
Quarterly Burn
$426K
Runway
1.1 mo
Revenue
$36K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| enekinragene inzadenovec | Phase 2 |
| labeling | Approved |
| ltx-03 | — |
Frequently asked questions
How many drug candidates are in ACURA PHARMACEUTICALS, INC's pipeline?
ACURA PHARMACEUTICALS, INC (ACUR) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ACURA PHARMACEUTICALS, INC's lead drug candidate?
ACURA PHARMACEUTICALS, INC's most advanced tracked candidate is enekinragene inzadenovec (Phase 2) for Osteoarthritis (OA) of the Knee.
What is ACURA PHARMACEUTICALS, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ACURA PHARMACEUTICALS, INC has approximately 1.1 months of cash runway.
What is ACURA PHARMACEUTICALS, INC's market capitalization?
ACURA PHARMACEUTICALS, INC's market capitalization is approximately $20K.
Who is the CEO of ACURA PHARMACEUTICALS, INC?
Mr. Robert B. Jones is the chief executive officer of ACURA PHARMACEUTICALS, INC (ACUR).
Get the full picture on ACURA PHARMACEUTICALS, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.